HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pilot liquid emulsion for asthma

This article was originally published in The Tan Sheet

Executive Summary

Airozin medical food for dietary maintenance of asthma is slated to launch April 7 at supermarkets, drugstores in the Carolinas, Pilot says. AC Nielsen will test direct and retail marketing to gauge success, firm notes. Airozin launch has been postponed twice, most recently due to flavor reformulation; product now is a mint, rather than citrus-flavored, liquid emulsion. Previously, the Charleston, S.C.-based firm delayed launch plans while awaiting the completion of clinical trials supporting product's efficacy (1"The Tan Sheet" Nov. 4, 2002, p. 16). Two studies, one on Airozin's safety and pharmacokinetics, are slated for publication in the March Clinical Therapeutics. Firm is sponsoring Charleston Asthma Summit April 10 to educate physicians, pharmacists, advocacy groups on asthma management...

You may also be interested in...



Pilot’s Airozin Medical Food For Asthma To Launch By Year End

Pilot Therapeutics plans to introduce its asthma maintenance therapy, Airozin, by the end of 2002 after a six-month delay, the company said

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel